AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) (AURORA)
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis
Sponsor: Tobira Therapeutics, Inc.
Terminated
This study was terminated early due to lack of efficacy based on the results of the planned interim analysis of Part 1 data.
Other terminated trials from Tobira Therapeutics, Inc.
More terminations from Tobira Therapeutics, Inc.
Other Nonalcoholic Steatohepatitis trials with similar outcome
This PHASE3 trial investigates Nonalcoholic Steatohepatitis and is currently terminated or withdrawn. Tobira Therapeutics, Inc. leads this study, which shows 24 recorded versions since 2017 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
24 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Apr 2022 [monthly]
Terminated PHASE3
▶ Show 19 earlier versions
-
May 2021 — Dec 2021 [monthly]
Terminated PHASE3
-
Feb 2021 — May 2021 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE3
Status: Active Not Recruiting → Recruiting
-
Sep 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE3
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE3
-
May 2020 — Jul 2020 [monthly]
Recruiting PHASE3
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE3
-
Feb 2020 — Apr 2020 [monthly]
Recruiting PHASE3
-
Nov 2019 — Feb 2020 [monthly]
Recruiting PHASE3
-
Apr 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Feb 2019 — Apr 2019 [monthly]
Recruiting PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Dec 2017 — Mar 2018 [monthly]
Recruiting PHASE3
-
May 2017 — Dec 2017 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — May 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Tobira Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Adelaide, Australia , Almería, Spain , Amiens, France , Angers, France , Arlington, United States , Athens, United States , Atlanta, United States , Aventura, United States , Badalona, Spain and 257 more locations